BillionToOne Swings To Profit In Q3; Sees Q4 Revenue Soaring Up To 100%

BillionToOne reported Q3 2025 net income of $1.5 million ($0.10/share) versus a $14.9 million loss a year earlier, as revenue jumped 117% to $83.5 million driven by a 52% increase in tests and a 44% rise in average selling price; gross profit rose to $58.4 million with margin expanding to 70% (from 53%) and operating income of $9.6 million. The company held $195.2 million in cash at quarter-end, generated $6.2 million of positive cash flow in Q3 and completed an IPO in November 2025 that raised $314 million gross (~$286.4 million net); it guided Q4 revenue of $84–$90 million (86–100% YoY) and full-year 2025 revenue of $293–$299 million (93–96% growth). The results reflect improving unit economics and pricing power across its UNITY NIPT and Northstar ctDNA franchises, providing balance-sheet runway for continued commercialization; shares closed at $109.53, up 4.65%.

Analysis

BillionToOne reported a return to profitability in Q3 2025 with net income available to common shareholders of $1.5 million ($0.10/share) versus a $14.9 million loss a year earlier, on revenue that surged 117% to $83.5 million from $38.4 million. Growth was driven by a 52% increase in tests delivered to 165,000 and a 44% rise in average selling price, which together lifted gross profit to $58.4 million and expanded gross margin to 70% from 53% a year ago.

Operating income turned positive at $9.6 million versus an operating loss of $12.6 million in Q3 2024, and the company generated $6.2 million of positive cash flow in the quarter while holding $195.2 million of cash at September 30, 2025. The November IPO raised $314.0 million gross (approximately $286.4 million net), materially extending runway to commercialize UNITY and the Northstar oncology franchise.

Management guided Q4 revenue of $84–$90 million (86–100% YoY) and full-year 2025 revenue of $293–$299 million (93–96% growth versus $153 million in 2024), underpinning the stock move to $109.53 (range $88–$138.70). Key risks to monitor are sustainability of higher ASPs, continued test-volume growth, and margin preservation as commercialization scales.

Key Decisions for Investors

• Consider initiating or adding to a position to capture accelerating revenue and margin expansion given Q3 profitability and strong guidance, but size exposure given commercialization execution risk
• Monitor quarterly metrics closely—tests delivered, average selling price, cost-per-test, and cash burn—to validate the company’s ability to sustain 70% gross margins and the implied revenue trajectory
• Use the post-IPO cash cushion and $195.2M cash balance as a positive signal for near-term runway, but consider staged buying or protective sizing given the stock’s $88–$138.70 trading range and potential volatility